Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Total Revenue of $44.52 million for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $44.52M +17.6% |
$37.87M -4.3% |
$39.55M -5.9% |
$42.01M +16.7% |
$35.99M -3.9% |
$37.44M +8.9% |
| Revenue (ASC 606) | $44.52M +17.6% |
$37.87M -4.3% |
$39.55M -5.9% |
$42.01M | — | — |
| Net Income | -$2.84M +56.2% |
-$6.48M -3.2% |
-$6.28M -12.7% |
-$5.57M -58.8% |
-$3.51M -5.0% |
-$3.34M +5.6% |
| Diluted EPS | -$0.19 +58.7% |
-$0.46 -4.5% |
-$0.44 -15.8% |
-$0.38 -58.3% |
-$0.24 -9.1% |
-$0.22 +4.3% |
| Total Assets | $76.82M +1.6% |
$75.58M -7.6% |
$81.78M -12.0% |
$92.93M +10.0% |
$84.46M -12.4% |
$96.46M -7.7% |
| Cash and Equivalents | $11.44M -36.3% |
$17.96M -2.0% |
$18.32M -7.3% |
$19.76M -26.9% |
$27.04M +9.2% |
$24.75M -12.3% |
| Stockholders Equity | $24.88M +8.9% |
$22.85M -22.8% |
$29.60M -18.4% |
$36.27M -15.3% |
$42.81M -8.9% |
$46.99M -8.1% |
| R&D Expense | $5.57M +15.6% |
$4.82M -17.4% |
$5.83M -12.8% |
$6.69M +17.7% |
$5.68M -1.5% |
$5.77M -15.9% |
| Operating Income | -$2.79M +56.6% |
-$6.43M +32.7% |
-$9.55M -67.5% |
-$5.70M +25.7% |
-$7.68M -20.3% |
-$6.38M +31.3% |
| Shares Outstanding | 14.96M +7.2% |
13.95M -1.2% |
14.12M -1.7% |
14.37M -2.6% |
14.74M -1.6% |
14.99M -1.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.29M | -8.7% | -23.5% |
| Revenue (ASC 606) | September 30, 2025 | $8.29M | -8.7% | -23.5% |
| Net Income | September 30, 2025 | -$1.94M | -25.7% | -162.0% |
| Diluted EPS | September 30, 2025 | -$0.13 | -18.2% | -160.0% |
| Total Assets | September 30, 2025 | $65.90M | -14.1% | -3.0% |
| Cash and Equivalents | September 30, 2025 | $15.20M | -13.0% | -5.5% |
| Stockholders Equity | September 30, 2025 | $26.12M | +5.4% | -6.7% |
| R&D Expense | September 30, 2025 | $1.25M | -4.0% | -14.6% |
| Operating Income | September 30, 2025 | -$1.97M | -16.0% | -162.9% |
| Shares Outstanding | September 30, 2025 | 14.96M | +6.8% | -0.0% |
- CUMBERLAND PHARMACEUTICALS INC reported Total Revenue of $44.52 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +17.6% in Total Revenue compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Revenue (ASC 606) of $44.52 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +17.6% in Revenue (ASC 606) compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Net Income of -$2.84 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +56.2% in Net Income compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Diluted EPS of $0.19 per share (loss) for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +58.7% in Diluted EPS compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Total Assets of $76.82 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +1.6% in Total Assets compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Cash and Equivalents of $11.44 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed a decrease of -36.3% in Cash and Equivalents compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Stockholders Equity of $24.88 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +8.9% in Stockholders Equity compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported R&D Expense of $5.57 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +15.6% in R&D Expense compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Operating Income of -$2.79 million for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +56.6% in Operating Income compared to the prior fiscal year.
- CUMBERLAND PHARMACEUTICALS INC reported Shares Outstanding of 14.96 million shares for fiscal year 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +7.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: